Deltin-based Adjuvant Development

Deltin-based Adjuvant Development

There is a constant need for new adjuvants to enhance the immunogenicity of vaccines such as human immunodeficiency virus (HIV), tuberculosis, malaria, and cancer. Deltin adjuvant has been shown to enhance humoral and cellular immune responses to a variety of antigens. With the help of our advanced Glyco™ Vaccine Development Platform, CD BioGlyco provides customers with the development service of Deltin adjuvant against different types of antigens.

Deltin Adjuvant

Inulin is one of the first polysaccharides thought to have immune effects. Currently, a more temperature-stable isoform of inulin, δ-inulin (Deltin), has been identified with adjuvant activity superior to earlier γ-inulin. Deltin adjuvant has been reported to be effective in animal models of HIV, avian influenza (H5N1), Japanese encephalitis, and African Horse Sickness vaccines. Deltin adjuvant has the remarkable feature of low reactogenicity and enhances cellular immunity and humoral immunity to antigens. It can enhance the production of antigen-specific IgA, IgM, and IgG while inducing antigen-specific CD4+ and CD8+ memory T cell responses.

Deltin-based Adjuvant Development

Action Mechanism of Deltin Adjuvant

Deltin adjuvant represents a novel human adjuvant that enhances the body's humoral immunity and cellular immunity. However, the action mechanism of Deltin adjuvant has not been fully elucidated. It is driven by interaction with antigen-presenting cells (APC). In addition, Deltin adjuvant failed to induce NFkB activation and inflammatory cytokine production in human monocytes or murine splenocytes, which may potentially explain its low reactogenicity. Although most immunization studies of Deltin adjuvant have been performed in mice, its adjuvant activity has been validated in a variety of animals.

Deltin Adjuvant Development Services

Deltin Adjuvant has successfully enhanced vaccine immunogenicity across multiple antigen types and is effective in all animal species tested. CD BioGlyco provides Deltin-based adjuvant development services to customers. Our services include but are not limited to:

  • Deltin adjuvant development for influenza vaccines

Inactivated influenza vaccine adjuvanted with Deltin can enhance serum neutralizing antibody titers in mice.

  • Deltin adjuvant development for pulmonary anthrax

Deltin adjuvant can enhance vaccine protection against pulmonary anthrax.

  • Deltin adjuvant development for Japanese encephalitis virus (JEV)

The addition of Deltin adjuvant to inactivated JEV antigen can enhance neutralizing antibody responses in immunized mice and horses.

  • Deltin adjuvant development for the severe acute respiratory syndrome (SARS)

Deltin adjuvant can enhance neutralizing antibody responses against SARS in a mouse model.

CD BioGlyco is a leader in carbohydrate-based adjuvant development, providing our customers with cost-effective, high-quality, and hassle-free Deltin-based adjuvant development services. If you are interested in our services, please contact us directly.


  1. Petrovsky, N.; Cooper, P.D. Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety. Vaccine. 2015, 33(44):5920-5926.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.